Target Name: MIR24-1
NCBI ID: G407012
Review Report on MIR24-1 Target / Biomarker Content of Review Report on MIR24-1 Target / Biomarker
MIR24-1
Other Name(s): miR-24-1 | MIR189 | hsa-mir-24-1 | hsa-miR-24-3p | MicroRNA 24-1 | MIRN24-1 | microRNA 24-1 | miRNA24-1 | hsa-miR-24-1-5p

miR-24-1: A Promising Drug Target and Biomarker for the Treatment of Cancer

miR-24-1, a microRNA (miRNA), is a non-coding RNA molecule that plays a crucial role in regulating gene expression in various organisms, including humans. It is expressed in a variety of tissues and has been implicated in various biological processes, including cell growth, apoptosis, and inflammation. In recent years, the discovery of miR-24-1 as a potential drug target and biomarker has gained significant interest due to its potential utility in cancer treatment. In this article, we will explore the life cycle, function, and potential therapeutic applications of miR-24-1, as well as its potential as a biomarker for cancer diagnosis and treatment.

Life Cycle and Function

miR-24-1 is a microRNA that is expressed in various tissues, including muscle, heart, kidney, liver, and brain. It is typically expressed in high levels in the cytoplasm and is involved in the regulation of gene expression, cell growth, and apoptosis.

One of the most significant functions of miR-24-1 is its role in cell apoptosis. miR-24-1 has been shown to play a role in the regulation of cell apoptosis, which is a natural process that helps remove damaged or dysfunctional cells from the body to prevent the spread of disease.

In addition to its role in apoptosis, miR-24-1 has also been shown to contribute to the regulation of cell growth. By regulating the expression of genes involved in cell growth and differentiation, miR-24-1 has been shown to play a role in the regulation of tissue growth and development.

Potential Therapeutic Applications

The potential therapeutic applications of miR-24-1 are vast, and its potential as a drug target and biomarker make it an attractive target for cancer treatment.

One of the most promising applications of miR-24-1 is its potential as a drug target for breast cancer. miR-24-1 has been shown to be involved in the regulation of cell growth and apoptosis, which are both critical processes that are disrupted in breast cancer cells. Therefore, targeting miR-24-1 with drugs that inhibit its function could be a promising strategy for the treatment of breast cancer.

Another potential application of miR-24-1 is its potential as a biomarker for cancer diagnosis and treatment. miR-24-1 has been shown to be expressed in various types of cancer, including breast, lung, and ovarian cancer. Therefore, using miR-24-1 as a biomarker for cancer diagnosis and treatment could be a promising strategy for the early detection and treatment of cancer.

Conclusion

In conclusion, miR-24-1 is a microRNA that plays a critical role in regulating gene expression in various organisms. Its role in cell apoptosis and cell growth makes it an attractive target for cancer treatment. The potential therapeutic applications of miR-24-1 are vast, and its potential as a drug target and biomarker make it an exciting area of research. Further studies are needed to fully understand the mechanisms of miR-24-1 and its potential as a therapeutic agent.

Protein Name: MicroRNA 24-1

The "MIR24-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR24-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR24-2 | MIR2467 | MIR25 | MIR2681 | MIR2682 | MIR26A1 | MIR26A2 | MIR26B | MIR27A | MIR27B | MIR28 | MIR2861 | MIR2909 | MIR296 | MIR297 | MIR298 | MIR299 | MIR29A | MIR29B1 | MIR29B2 | MIR29B2CHG | MIR29C | MIR300 | MIR301A | MIR301B | MIR302A | MIR302B | MIR302C | MIR302D | MIR302E | MIR302F | MIR3059 | MIR3064 | MIR3065 | MIR3074 | MIR3085 | MIR30A | MIR30B | MIR30C1 | MIR30C2 | MIR30D | MIR30E | MIR31 | MIR3115 | MIR3116-1 | MIR3116-2 | MIR3117 | MIR3118-1 | MIR3118-2 | MIR3118-3 | MIR3118-4 | MIR3118-5 | MIR3118-6 | MIR3119-1 | MIR3119-2 | MIR3120 | MIR3121 | MIR3122 | MIR3123 | MIR3124 | MIR3125 | MIR3126 | MIR3127 | MIR3128 | MIR3129 | MIR3130-1 | MIR3130-2 | MIR3131 | MIR3132 | MIR3133 | MIR3134 | MIR3135A | MIR3135B | MIR3136 | MIR3137 | MIR3138 | MIR3139 | MIR3140 | MIR3141 | MIR3142 | MIR3142HG | MIR3143 | MIR3144 | MIR3145 | MIR3146 | MIR3147 | MIR3147HG | MIR3148 | MIR3149 | MIR3150A | MIR3150B | MIR3151 | MIR3152 | MIR3153 | MIR3154 | MIR3155A | MIR3155B | MIR3156-1 | MIR3156-2 | MIR3156-3